Reduced EAAT1 and EAAT2 expression and concurrently abundant system Xc− activity (old nomenclature of xCT activity) results in a net balance shift towards glutamate release, thus promoting glioma progression. This evidence concerns the gene SLC1A2 and central nervous system cancer.